Literature DB >> 3875661

Prosthetic valve endocarditis due to methicillin-resistant Staphylococcus epidermidis and Micrococcus species successfully treated with rifampicin combined with other antibiotics.

R Colebunders, J P Ursi, S Pattyn, J Snoeck.   

Abstract

Two patients with prosthetic valve endocarditis due to methicillin-resistant Gram-positive cocci (Staphylococcus epidermidis and Micrococcus spp.) are described. They were successfully treated with rifampicin combined first with an aminoglycoside and later with co-trimoxazole or co-trimoxazole plus vancomycin. The addition of rifampicin to these antibiotics resulted in enhanced serum bactericidal activity. High doses of rifampicin (1200-1800 mg) for 7-8 weeks did not cause any serious side-effect. Surgery was not required. During surveillance for more than 2 years endocarditis did not recur.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875661     DOI: 10.1016/s0163-4453(85)90954-5

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  3 in total

Review 1.  Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

Authors:  A B Morris; R B Brown; M Sands
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

Review 2.  Endocarditis due to Kytococcus schroeteri: case report and review of the literature.

Authors:  Basma Mnif; Inès Boujelbène; Fouzia Mahjoubi; Radouane Gdoura; Imen Trabelsi; Sana Moalla; Imed Frikha; Samir Kammoun; Adnane Hammami
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 3.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.